Mark is a clinical academic with an interest in translational and applied aspects of immunology. Training in molecular and clinical medicine at Oxford University, he has gone onto complete the prestigious master’s course in Medical Immunology at King’s College London.
Motivated by our limited understanding of infections of the upper airway and available therapeutics, he is a key investigator of the Burden of Infection in Primary Antibody Deficiency (BIPAD) project- representing the most intensive study in this field to date. His wider research interests included international collaboration in whole exome/genome sequencing programmes and have provided novel insights into overlaps between antibody deficiency and psychiatry. He is currently supported in pre-doctoral research by the Wellcome Trust Clinical Primer Award scheme to explore the immunomodulatory effects of the antipsychotic clozapine. Together these projects help provide important insights to factors governing infection susceptibility, and impact future studies driving the development of better treatments.